Global Wound Irrigation System Market - 2024-2031

Report Overview

The Global Wound Irrigation System Market reached US$ 283 million in 2023 and is expected to reach US$ 372.95 million by 2031, growing at a CAGR of 3.6% during the forecast period 2024-2031.

A Wound Irrigation system is described as the flow of a solution through an exposed fracture surface to reduce microbial colonization, to remove apparent foreign particles and wound exudates. Wound irrigation, that is washing out a wound before wound closure) aims to reduce the microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field before site closure. When wound irrigation is done correctly, it speeds up the healing process and reduces the risk of complications.

The only types of wounds that you should avoid irrigating are those that are actively bleeding. The primary advantages of irrigation are that it helps keep a healthy, moist environment that's conducive to cleaning, assists debridement, and improves the wound healing process. When done correctly, it reduces the amount of time a wound takes to heal and can help minimize scarring. Since wound irrigation is fairly straightforward, it's easy to perform anywhere you are, regardless of the location of your wound.

Market Dynamics: Drivers

Increasing prevalence of chronic wounds

The demand for the global wound irrigation system market is driven by multiple factors. The rising prevalence of chronic wounds propels the market growth.

Furthermore, the demand for this market will be fueled by the increase in surgical procedures in recent times. The wound irrigation system plays a very vital role in various surgical procedures. The increase in the population of older people who are 60 years and above is also one of the driving factors. Technological advancements in this field are also one of the major driving factors in the wound irrigation system market.

Chronic wounds are those that do not progress through a normal, orderly, and timely sequence of repair. For instance, according to an article posted by Wounds International, in December 2023, according to one estimate, out of 77 million individuals with diabetes, 25% develop a diabetic foot ulcer. Venous ulcers are the most severe and debilitating outcome of chronic venous insufficiency in the lower limbs, accounting for 80% of lower-extremity ulcerations. The prevalence of chronic wounds in India is estimated to be 4.5 per 1,000 people.

According to facs.org, it is estimated that 1 to 2 percent of the population in developed countries will suffer from a chronic wound in their lifetime. According to the International Diabetes Federation, 10.5% of the adult global population (20 - 79 years) is estimated to have diabetes with almost half of the people being unaware of it.

Restraints

Factors such as high cost associated with advanced wound systems, limited availability in developing countries, and hazards caused due to infection are expected to hamper the market.

Market Segment Analysis

The global wound irrigation system market is segmented based on product type, application, end-user, and region.

The segment chronic wounds accounted for approximately 44.1% of the global wound irrigation system market share

The chronic wounds segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and technological advancements for chronic wound irrigation would drive this market.

Due to the increase in chronic diseases in the global population, there has been an increase in chronic wounds in recent times. According to nih.gov, venous leg ulcers are a major clinical challenge they are the result of chronic venous insufficiency(CVI) and venous hypertension. Their three-month healing rate is estimated at 40 %and once healed up to 80% of patients develop a recurrence within 3 months. The prevalence of VLUs is reported around 1.08% and the incidence is up to 1.33%. The prevalence and incidence of VLU increase with age.

Pressure Ulcer is a localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. It is estimated that about 2.5 million hospitalizations in the United States are due to pressure ulcers. In the UK, 4% of the total treatment costs are allocated for the treatment of pressure ulcers. In addition to the extra costs spent on the treatment of pressure ulcers, there are bed reservations and associated costs arising from hospitalization. These ulcers also cause the nursing staff an increase in workload by 50%

Market Geographical Share

North America accounted for approximately 46.3% of the global wound irrigation system market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic wounds, growing awareness among people, and the funding allotted by the government in this region help to propel the market.

According to facs.org, In the United States, it is reported that chronic wounds affect approximately 6.5 million patients. The US government allotted a very hefty funding regarding wound care. The financial burden imposed by chronic wounds on society is substantial. In the United States, more than $25 billion is spent by the healthcare system on treating wound-related complications per year. Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States. This fraction is larger in the elderly. These wounds can lead to a range of complications and healthcare costs.

The technological advancements in the region of North America are one of the reasons for the largest market share. The U.S. Centers for Medicare and Medicaid Services had proposed a revision of its local coverage determination limiting the use of skin substitute grafts/cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the U.S. Medicare population.

The U.S. Food and Drug Administration (FDA) has renewed its focus on addressing non-healing chronic wounds and has outlined efforts to address identified barriers to product development for non-healing chronic wounds. The new approach emphasizes engaging key wound-healing stakeholders, including academia, professional associations, patient groups, reimbursement organizations, and industry. Finally, recent advances demonstrating that wounds closed by the current FDA definition of wound closure may remain functionally open because of deficiencies in the restoration of barrier function warrant revisiting the wound closure endpoint.

Market Segmentation

By Product Type

• Manual Operated
• Syringe Based
• Spray Based
• Nozzle Based
• Battery Operated

By Application

• Acute Wounds
• Surgical Wounds
• Traumatic Wounds
• Burnt Wounds
• Chronic Wounds
• Diabetic foot Ulcers
• Venous Ulcers
• Pressure Ulcers
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centre
• Homecare
• Academic and Research Institutes
• Others

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe
• South America
• Brazil
• Argentina
• Rest of South America
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the global wound irrigation system market include Zimmer Biomet, Stryker Corporation, Bionix Llc., Irrimax Corporation, Cooper Surgical Inc., Westmed Inc., Becton Dickson and Company, Essity Health & Medical, Centurion Service Group, and Hopkins Medical Products among others.

Key Developments

• In June 2021, Irrimax Corporation, manufacturer of irrisept, announced new clearance from the U.S. Food and Drug Administration (FDA), making irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market. Today, more than 2,000 U.S. hospitals are using the irrisept product totaling more than 2 million lifetime uses.
• In April 2021, the FDA notified that Zimmer Biomet's single-step application wound irrigation solution, XPERIENCE No Rinse Antimicrobial Solution, has been cleared in the U.S. for immediate distribution. The device was originally submitted to the FDA as MIS Solution but is now being marketed as XPERIENCE.
• In May 2021, BD (Becton, Dickinson, and Company) a leading global medical technology company, announced today the availability of BD Surgiphor(TM) Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.

Why Purchase the Report?

• To visualize the global wound irrigation system market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global wound irrigation system market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies